151 related articles for article (PubMed ID: 34231501)
1. Effect of unfractionated heparin and low molecular weight heparin on the clotting of platelet-reduced whole blood: an in-vitro study utilizing thromboelastography.
Chung J; Stevic I; Gantioqui J; Atkinson H; Chan AKC; Chan HHW
Blood Coagul Fibrinolysis; 2021 Jul; 32(5):305-311. PubMed ID: 34231501
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban and dabigatran did not affect clotting profiles in plasma reconstituted with varying levels of autologous platelets to the same degree as heparin when evaluated using thromboelastography.
Gantioqui J; Stevic I; Atkinson H; Chan AKC
Blood Coagul Fibrinolysis; 2018 Sep; 29(6):521-527. PubMed ID: 29965810
[TBL] [Abstract][Full Text] [Related]
3. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
[TBL] [Abstract][Full Text] [Related]
4. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE
Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226
[TBL] [Abstract][Full Text] [Related]
5. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
Mousa SA; Linhardt R; Francis JL; Amirkhosravi A
Thromb Haemost; 2006 Dec; 96(6):816-21. PubMed ID: 17139378
[TBL] [Abstract][Full Text] [Related]
6. Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.
Junqueira DR; Zorzela LM; Perini E
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007557. PubMed ID: 28431186
[TBL] [Abstract][Full Text] [Related]
7. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation.
Zmuda K; Neofotistos D; Ts'ao CH
Am J Clin Pathol; 2000 May; 113(5):725-31. PubMed ID: 10800406
[TBL] [Abstract][Full Text] [Related]
8. Platelets are dominant contributors to hypercoagulability after injury.
Harr JN; Moore EE; Chin TL; Ghasabyan A; Gonzalez E; Wohlauer MV; Banerjee A; Silliman CC; Sauaia A
J Trauma Acute Care Surg; 2013 Mar; 74(3):756-62; discussion 762-5. PubMed ID: 23425732
[TBL] [Abstract][Full Text] [Related]
9. Thromboelastography and Traditional Coagulation Testing in Non-ICU-Admitted Patients with Acute Kidney Injury: An Observational Cohort Study.
Liu J; Liu Z; Zhao T; Su T; Jin Q
Am J Nephrol; 2023; 54(5-6):208-218. PubMed ID: 37364534
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Tsujimoto H; Tsujimoto Y; Nakata Y; Fujii T; Takahashi S; Akazawa M; Kataoka Y
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD012467. PubMed ID: 33314078
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of different low-molecular-weight heparins (LMWHs) and drug interactions with LMWH: implications for management of vascular disorders.
Mousa SA
Semin Thromb Hemost; 2000; 26 Suppl 1():39-46. PubMed ID: 11011805
[TBL] [Abstract][Full Text] [Related]
12. The effects of unfractionated heparin, low molecular weight heparin and danaparoid on the thromboelastogram (TEG): an in-vitro comparison of standard and heparinase-modified TEGs with conventional coagulation assays.
Coppell JA; Thalheimer U; Zambruni A; Triantos CK; Riddell AF; Burroughs AK; Perry DJ
Blood Coagul Fibrinolysis; 2006 Mar; 17(2):97-104. PubMed ID: 16479191
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of coagulation and platelet adhesion to extracellular matrix by unfractionated heparin and a low molecular weight heparin.
Krupinski K; Basic-Micic M; Lindhoff E; Breddin HK
Blut; 1990 Nov; 61(5):289-94. PubMed ID: 2176900
[TBL] [Abstract][Full Text] [Related]
14. Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients.
Junqueira DR; Perini E; Penholati RR; Carvalho MG
Cochrane Database Syst Rev; 2012 Sep; (9):CD007557. PubMed ID: 22972111
[TBL] [Abstract][Full Text] [Related]
15. A low-molecular-weight heparin (Kabi 2165, 'Fragmin') in repeated use for haemodialysis: prevention of clotting and prolongation of the venous compression time in comparison with commercial unfractionated heparin.
Anastassiades E; Ireland H; Flynn A; Lane DA; Curtis JR
Nephrol Dial Transplant; 1990; 5(2):135-40. PubMed ID: 2162506
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Tsujimoto H; Tsujimoto Y; Nakata Y; Fujii T; Takahashi S; Akazawa M; Kataoka Y
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD012467. PubMed ID: 32164041
[TBL] [Abstract][Full Text] [Related]
17. The management of heparin-induced thrombocytopenia.
Keeling D; Davidson S; Watson H;
Br J Haematol; 2006 May; 133(3):259-69. PubMed ID: 16643427
[TBL] [Abstract][Full Text] [Related]
18. In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves.
Maegdefessel L; Linde T; Krapiec F; Hamilton K; Steinseifer U; van Ryn J; Raaz U; Buerke M; Werdan K; Schlitt A
Thromb Res; 2010 Sep; 126(3):e196-200. PubMed ID: 20659761
[TBL] [Abstract][Full Text] [Related]
19. Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus.
Napolitano M; Saccullo G; Marietta M; Carpenedo M; Castaman G; Cerchiara E; Chistolini A; Contino L; De Stefano V; Falanga A; Federici AB; Rossi E; Santoro R; Siragusa S; ; ; De Stefano V; Falanga A; Tosetto A; Avvisati G; Carpenedo M; Federici AB; Marietta M; Napolitano M; Rossi E; Santoro C; Castaman G; Cerchiara E; Chistolini A; Contino L; Mazzucconi MG; Nichele I; Russo L; Santi R; Santoro RC; Siragusa S; Tagariello G
Blood Transfus; 2019 May; 17(3):171-180. PubMed ID: 30418130
[TBL] [Abstract][Full Text] [Related]
20. Postinjury hyperfibrinogenemia compromises efficacy of heparin-based venous thromboembolism prophylaxis.
Harr JN; Moore EE; Chin TL; Ghasabyan A; Gonzalez E; Wohlauer MV; Sauaia A; Banerjee A; Silliman CC
Shock; 2014 Jan; 41(1):33-9. PubMed ID: 24351527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
